Wordt geladen...
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan
AIMS: A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m(2)), which suggests that these genes might predict outcomes to irinotecan-based...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2009
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2748108/ https://ncbi.nlm.nih.gov/pubmed/19604089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs.09.35 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|